Effect of gonadotropin-releasing hormone agonist on uterine fibroids and its effect on immune function

VernacularTitle:促性腺激素释放激素激动剂治疗子宫肌瘤及对免疫功能的影响
Author: Ai MA ; Dianjun WEI
Keywords: GnRH-a; mifepristone; uterine myoma; serum sex hormone levels; immunologic function
From: Chinese Journal of Biochemical Pharmaceutics 2017;37(7):68-70
CountryChina
Language:Chinese
Abstract: Objective To investigate the hysteromyoma treated with the gonadotropin releasing hormone agonist(GnRH-a)and the impact on immunologic function.Methods 130 cases selected from the patients with hysteromyoma enrolled from January 2016 to December 2016 in hospital have been randomly divided into two groups.The control group has been treated with mifepristone while the study group GnRH-a.Results The sizes of uterus and myoma of both groups have no significant difference before treatment.After treatment, both of them are significantly improved, and those of the study group is significantly smaller than that of the control group(P<0.05).The levels of serum sex hormone and immunologic function of both groups have no significant difference before treatment.They are both improved after treatment, and the study group is significantly better than the control group(P<0.05).Conclusion Applying GnRH-a therapy to the patients with uterine myoma benefits for improving the therapeutic effect, which can improve the serum sex hormone levels and immunologic function.